Investigators pooled data from 4 trials to evaluate risk for recurrence in patients with intermediate risk non-muscle-invasive bladder cancer.
AMHERST, Mass. (WWLP) – A University of Massachusetts Amherst research team has been awarded up to $3.45 million from the National Institutes of Health to help develop a new way to prevent the ...
The PD-1 and PD-L1 inhibitors competitive landscape report delivers important insights into approved as well as ongoing research of 200+ pipeline PD-1 and PD-L1 inhibitor drugs, clinical strategies, ...
Genomics says it is on track to build out a CLIA-certified laboratory set to open next year, part of the spatial and ...
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead ...
Morning Overview on MSN
Regulators cleared Keytruda with chemo before and after surgery for aggressive bladder cancer
Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the ...
SurvivorNet on MSN
New approval means more bladder cancer patients can access powerful immunotherapy combination: What to know about Keytruda + Padcev
A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...
A young boy born a world away finds hope in a forever family in Bay Village and beats a cancer that could have been fatal.
Asia-Pacific will be the fastest-growing region. Key players include Roche, Thermo Fisher, Illumina, Agilent Technologies, ...
Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise risk—read now.
A Southland cancer patient who needs regular surgery to control the growth has faced weeks of delays after a cancellation.
Detailed price information for Engene Therapeutics Inc (ENGN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results